Case Reports in Oncological Medicine最新文献

{"title":"Leptomeningeal Carcinomatosis and Myelophthisic Anemia as Initial Manifestations of Metastatic Lobular Breast Cancer.","authors":"Ogaga Urhie, Kally Dey, Kirtan Patolia, Shiraz Fidai, Michael Alebich","doi":"10.1155/crom/5631996","DOIUrl":"10.1155/crom/5631996","url":null,"abstract":"<p><p>Breast cancer can spread to the brain and bone, usually presenting as parenchymal and osteoblastic lesions, respectively. We present a unique case of a 59-year-old woman undergoing treatment for invasive lobular breast cancer who presented with nausea, vomiting, headache, and generalized weakness. Her clinical presentation and subsequent evaluation led to a discovery of leptomeningeal carcinomatosis and myelophthisic anemia presenting simultaneously as her initial metastases. She was treated with weekly paclitaxel and intrathecal methotrexate, with noted cerebrospinal fluid response. She continues to follow up with the oncology clinic.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5631996"},"PeriodicalIF":0.6,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies.","authors":"Morgan M Puglisi, Natasha N Dziarnowski, Bohdan Baralo, Hetal Vachhani","doi":"10.1155/crom/5879510","DOIUrl":"10.1155/crom/5879510","url":null,"abstract":"<p><p><b>Introduction:</b> Deficiency in <i>BRCA</i> genes leads to impediment in DNA repair and is associated with an increased lifetime risk of breast, ovarian, prostate, and pancreatic cancer and melanoma. Lynch syndrome is caused by inherited mutations in genes responsible for DNA mismatch repair, with resultant increase in lifetime risk of colorectal, endometrial, ovarian, stomach, urinary, pancreatic, and CNS malignancies. Here, we present a patient with a rare coexistence of both <i>BRCA2</i> and <i>PSM2</i> mutation in the setting of metastatic pancreatic and prostate cancer. <b>Case Presentation:</b> The patient was initially diagnosed with metastatic prostate adenocarcinoma at the age of 57, when a screening PSA of 22.9 warranted biopsy and staging scans revealed involvement of the aortocaval lymph node. Treatment with androgen deprivation therapy with the addition of abiraterone and prednisone was initiated. Additionally, a PET scan showed a hypermetabolic isolated lung nodule, which upon wedge resection showed Stage I lung cancer. Three years later, a pancreatic mass and multiple liver lesions were found on a surveillance scan. Biopsy confirmed the diagnosis of pancreatic cancer, and germline testing revealed the coexistence of <i>BRCA2</i> and <i>PMS2</i> mutations. The patient completed four cycles of cisplatin and gemcitabine, followed by the initiation of olaparib as per the POLE study. About 12 months after the diagnosis of metastatic pancreatic cancer and 4 years after the diagnosis of metastatic prostate cancer, the patient has excellent control of the disease with performance status ECOG 0 and minimal side effects from maintenance therapy. <b>Conclusion:</b> This case presents a unique combination of two coexistent inherited syndromes with the approximate combined incidence of 1:357,000. The presence of two advanced malignancies in our patient underlines the cumulative effects of combined deficiency in the DNA repair pathway and possibly an even higher lifetime risk of cancer. This may explain the presence of lung cancer with a minimal smoking history of less than 10 pack years. PARP inhibitors may be effective in controlling metastatic pancreatic cancer, and thus, genetic counseling is important for this patient and his family members, who will need appropriate cancer screening. The probability of carrying two pathogenic variants may be expected to increase as a result of next-generation sequencing and germline testing.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5879510"},"PeriodicalIF":0.6,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report.","authors":"David Sánchez García, Beatriz Grau Mirete, Paula Rodríguez Payá, Asia Ferrández-Arias, Miguel Borregón-Rivilla, Antonio-David Lázaro-Sánchez, Javier-David Benítez-Fuentes","doi":"10.1155/crom/4483379","DOIUrl":"10.1155/crom/4483379","url":null,"abstract":"<p><p>Oligoprogression in MET Exon 14 skipping (METex14)-mutated non-small cell lung cancer (NSCLC) is clinically challenging, particularly when local therapies are contraindicated. We report the first documented case of a 62-year-old man with oligoprogressive METex14-positive NSCLC who achieved a sustained metabolic response following the addition of docetaxel to ongoing tepotinib therapy after progression on tepotinib monotherapy. Due to prior thoracic irradiation, reirradiation and surgical interventions were deemed not feasible, prompting this systemic combination to maintain MET inhibition while targeting resistant tumor clones. This strategy resulted in a partial metabolic response at the primary lung lesion and a sustained complete metabolic response in an adrenal metastasis. The regimen was generally well tolerated; however, Grade 3 peripheral edema required dose reduction of tepotinib. This case supports the potential role of systemic therapy intensification in METex14-driven NSCLC, highlighting the therapeutic value of continued MET inhibition beyond disease progression, particularly when local treatment and advanced molecular monitoring such as ctDNA are unavailable. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05439993.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4483379"},"PeriodicalIF":0.6,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of T-Large Granular Lymphocytic (T-LGL) Leukemia in a Patient With Rheumatoid Arthritis With Neutropenia and Low LGL Level.","authors":"Muhammad Daniyal, Anamm Polani, Pavel Bleik, Jeffrey Allerton","doi":"10.1155/crom/5013991","DOIUrl":"10.1155/crom/5013991","url":null,"abstract":"<p><p>T-large granular lymphocytic (T-LGL) leukemia is a rare hematological malignancy characterized by clonal expansion of cytotoxic T-cells resulting in cytopenias. The diagnostic criteria for T-LGL leukemia necessitated a sustained peripheral blood elevation of LGLs exceeding 2 × 10⁹/L for a minimum duration of 6 months, in the absence of an identifiable etiology. In most of the cases, it is associated with autoimmune disorders such as rheumatoid arthritis. As cytopenias, including neutropenia, can be an early manifestation of the disease, they may get confused with Felty's syndrome, resulting in delayed diagnosis and treatment. Hence, we are presenting a rare case of diagnosing T-LGL leukemia in a patient with rheumatoid arthritis with neutropenia and low LGL level.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5013991"},"PeriodicalIF":0.6,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esoteric Diagnostic Considerations for Small Round Cell Tumors in Biopsy Specimens With Extensive Negative Immunohistochemical Profiles: Utilizing Subtle Histopathological Features Prior to Molecular Testing.","authors":"Dong Ren, Ryan O'connell","doi":"10.1155/crom/5186729","DOIUrl":"10.1155/crom/5186729","url":null,"abstract":"<p><p>Small round cell tumors (SRCTs) are characterized by primitive round cells and a broad differential diagnosis due to their undifferentiated nature, making their diagnosis particularly challenging. Molecular testing is often essential for definitive classification; however, subtle histomorphological features can significantly narrow the differential diagnosis. Here, we present the case of a 44-year-old male who presented with a painless mass (up to 15.6 cm) in the left thigh. Histologic examination of the biopsy revealed solid sheets of monotonous small round cells with scant cytoplasm, hyperchromatic nuclei, and conspicuous nucleoli within the edematous to myxoid stroma. Notably, capillary-sized blood vessels were present throughout the tumor, which made BCOR-rearranged sarcomas, myxoid liposarcoma with small cell morphology, and GLI1-altered soft tissue tumors the main differential diagnoses. Classic morphology of myxoid liposarcoma was not present. Immunohistochemical (IHC) staining revealed that the tumor cells were diffusely positive for SOX11 but negative for SATB2, CD56, S100, and TLE1. This immunophenotype, combined with the histological findings, strongly suggested a diagnosis of myxoid liposarcoma with high-grade features. Fluorescence in situ hybridization (FISH) analysis confirmed a DDIT3 rearrangement, supporting this diagnosis. We hope this case will enhance pathologists' understanding and recognition of the importance of utilizing subtle histologic features to establish the differential diagnosis and accurately diagnose SRCTs in biopsy specimens prior to molecular testing.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5186729"},"PeriodicalIF":0.6,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Lung Adenocarcinoma Presenting With Cavitary and Consolidative Lung Findings: A Diagnostic Dilemma.","authors":"Abdalhakim Shubietah, Omar Hamadi, Mahmoud Doudein, Malak Ramzy Hroub, Muath Baniowda, Amer Abu-Shanab, Khalil Karim, Suliman Hamadneh","doi":"10.1155/crom/5007092","DOIUrl":"10.1155/crom/5007092","url":null,"abstract":"<p><p><b>Introduction:</b> Lung cancer is the leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) accounting for 85% of cases. Lung adenocarcinoma, the most common subtype, can mimic benign conditions like pneumonia, lung abscess, and interstitial lung disease due to its varied radiologic presentations and associated inflammation and fibrosis. This similarity can delay diagnosis, emphasizing the need for imaging and histopathological confirmation. <b>Case Presentation:</b> A 58-year-old male with a significant smoking history, hypertension, and GERD presented with a 5-month history of episodic epigastric pain, exacerbated by heavy meals, along with progressive respiratory symptoms, including shortness of breath, dry cough, and a 20-kg weight loss over 3 months. Upper endoscopy revealed gastric ulcers, a hiatal hernia, esophageal mucosal changes consistent with GERD, and <i>Helicobacter pylori</i> infection on biopsy, which was treated with triple therapy, resolving his gastrointestinal symptoms. However, his respiratory symptoms worsened, with increased dyspnea at rest, pleuritic chest pain, and a persistent cough. Chest CT showed multiple cavitating lung nodules, architectural distortion predominantly in the upper lobes, a large irregular lesion in the right lower lobe, and enlarged paratracheal, subcarinal, and distal paraesophageal lymph nodes. The patient was transferred to our facility for further evaluation. Whole-body CT revealed widespread bilateral cavitary lesions, lymphadenopathy, and a small hiatal hernia. Bronchoscopy with biopsy confirmed metastatic lung adenocarcinoma, with histopathology showing moderately differentiated adenocarcinoma, positive for TTF-1 and Napsin A and negative for PAX8. Cytology from bronchoalveolar lavage also confirmed malignancy, and PD-L1 immunostaining showed weak positivity in 15%-20% of tumor cells. The patient was diagnosed with metastatic lung adenocarcinoma and initiated on carboplatin and pemetrexed chemotherapy. Molecular testing was planned, and he was discharged for follow-up care. <b>Conclusion:</b> Our case of a 58-year-old male with cavitating lung nodules, significant weight loss, and progressive respiratory symptoms, initially misattributed to gastrointestinal disease, highlights the diagnostic complexity of lung adenocarcinoma. The biopsy-confirmed diagnosis of metastatic adenocarcinoma underscores the need for clinicians to maintain a high index of suspicion for malignancy in patients with atypical or nonspecific presentations. Early tissue diagnosis is crucial for timely treatment and improved outcomes, especially in cases involving cavitary lesions or persistent, unexplained symptoms.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5007092"},"PeriodicalIF":0.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Presentation of Nodular Melanoma and Epithelioid Cell Melanoma: Case Report.","authors":"Gianluca Gizzi, Dario Didona, Serge C Thal, Luca Scarsella","doi":"10.1155/crom/6396505","DOIUrl":"10.1155/crom/6396505","url":null,"abstract":"<p><p><b>Introduction:</b> The synchronous occurrence of melanomas of varying histological types is an uncommon event, with reported incidences ranging from 0.2% to 8.6%. <b>Case Report:</b> We present the case of a patient diagnosed with Stage IIB nodular melanoma and Stage IIIC epithelioid cell melanoma within a 3-month period. After surgical excision of both lesions, lymph node enlargement was observed in the obturator region, indicating metastatic spread. As a result, combined immunotherapy with nivolumab and ipilimumab was initiated. Nivolumab and ipilimumab were administered at doses of 1 and 3 mg/kg, respectively, every 3 weeks for a total of four doses. Thereafter, treatment was continued with nivolumab alone at a dose of 3 mg/kg every 2 weeks. The patient underwent three cycles of immunotherapy, initially combined with intravenous methylprednisolone, later transitioned to an oral regimen with dexamethasone. The patient initially demonstrated a favorable clinical response without adverse effects. However, after the third infusion, severe diarrhea developed, leading to daily fluid losses exceeding 8 L and associated hypokalemia. Therefore, methylprednisolone was administered intravenously (2 mg/kg/day). Additionally, the patient experienced a splenic infarction that resolved spontaneously without resulting in asplenia. At the most recent follow-up evaluation, no lymph node enlargement was detected, and surveillance continues at 3-month intervals. <b>Discussion:</b> Although rare, the simultaneous emergence of melanomas at distinct anatomical sites underscores the necessity for increased patient vigilance and comprehensive clinical monitoring to facilitate early detection and timely intervention. <b>Conclusion:</b> Prompt initiation of targeted immunotherapy may improve patient prognosis and outcomes.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"6396505"},"PeriodicalIF":0.6,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoimmunotherapy in Advanced, PD-1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases.","authors":"Golbarg Rahimi, Gino K In","doi":"10.1155/crom/4443916","DOIUrl":"10.1155/crom/4443916","url":null,"abstract":"<p><p>Cutaneous squamous cell carcinoma (cSCC) is one of the most prevalent malignancies worldwide, and a subset of patients, particularly immunocompromised individuals, will face heightened risks of metastasis and mortality. This report examines two cases of immunocompromised patients treated with a combination of platinum- and taxane-based chemotherapy together with PD-1 inhibition, having progressed after PD-1 monotherapy. The first patient, a 54-year-old man with HIV and recurrent metastatic cSCC, had rapid progression of disease while undergoing PD-1 inhibition with cemiplimab but later achieved tumor control when treated with pembrolizumab, carboplatin, and paclitaxel. The second patient, a 36-year-old man with cystic fibrosis and a history of lung transplantation, had no signs of response to cemiplimab but experienced a partial response when treated with cemiplimab, carboplatin, and paclitaxel. These cases suggest that combining chemotherapy with PD-1 inhibition may help overcome primary resistance to PD-1 therapy in advanced cSCC.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4443916"},"PeriodicalIF":0.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12279414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report.","authors":"Sam Plessers, Jeroen Mebis, Nina De Moor, Tim Wessels, Daisy Luyten, Annelies Requilé","doi":"10.1155/crom/8600200","DOIUrl":"10.1155/crom/8600200","url":null,"abstract":"<p><p>Hypercalcemia of malignancy is a well-known phenomenon in cancer patients, often associated with poor prognosis. The discovery of immune checkpoint inhibitors has revolutionised cancer therapy by improving prognosis in numerous different cancer types. Unfortunately, immune-related adverse events frequently arise, particularly with dual checkpoint inhibition. We present a case of severe hypercalcemia in a 65-year-old woman undergoing treatment for metastasised malignant melanoma. Eleven weeks after initiating ipilimumab-nivolumab, the patient developed severe hypercalcemia, along with inflammation and hepatitis. This was initially presumed to be due to hypercalcemia of malignancy, given the clinical examination, imaging findings and laboratory values potentially consistent with progressive disease. The hypercalcemia responded well to bisphosphonates, intravenous saline and methylprednisolone. Interestingly, fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) performed shortly after hospital discharge showed a complete metabolic remission, thereby making hypercalcemia of malignancy unlikely. Review of her medical history, imaging and laboratory revealed several features consistent with a sarcoid-like reaction. We hypothesise that this reaction led to elevated 1-alpha hydroxylase, thereby facilitating calcitriol-mediated hypercalcemia. In this report, we summarise previously published case reports on immune checkpoint inhibitor-induced hypercalcemia and discuss the various mechanisms that cause hypercalcemia in this rare immune-related adverse event. Immune checkpoint inhibitors can induce production of parathyroid hormone-related protein (PTHrP), calcitriol, and may cause hypocortisolaemia, all of which can disrupt calcium homeostasis. Through this case, we contribute to the growing body of evidence regarding hypercalcemia as an immune-related adverse event and aim to raise awareness among clinicians of this potential complication. Early recognition is critical for this life-threatening condition, as it can be refractory to conventional therapies and may necessitate corticosteroid therapy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"8600200"},"PeriodicalIF":0.6,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endometrial Stromal Sarcoma-Associated Hypereosinophilia: A Case Report.","authors":"Smriti Nair, Sanjna Shelukar, Sydney Kornbleuth, Grant Gillan, Emily Hansinger, Ruben Rhoades, Lakshmi Ravindran, Timothy Kuchera","doi":"10.1155/crom/5586309","DOIUrl":"10.1155/crom/5586309","url":null,"abstract":"<p><p>Eosinophilia is a common systemic reaction to allergy, parasitic infection, or drug hypersensitivity. Rarely, it manifests as a paraneoplastic phenomenon, most commonly secondary to hematologic malignancies or extensive metastatic disease in solid tumors. There is scarce literature attributing peripheral eosinophilia to solid organ malignancies, especially gynecologic malignancies. We present the first reported case of peripheral eosinophilia secondary to high-grade endometrial stromal sarcoma (HGESS). A postmenopausal woman presented with weakness, urinary incontinence, and marked peripheral eosinophilia. An unremarkable infectious workup prompted further imaging, which revealed a uterine mass. She underwent total hysterectomy with bilateral salpingo-oophorectomy, after which her eosinophilia resolved. Histopathology confirmed HGESS. One month later, the patient re-presented with recurrent eosinophilia and was found to have new metastatic lesions on CT abdomen/pelvis. She elected to pursue hospice care. This case highlights a rare and atypical presentation of an aggressive uterine malignancy underscoring peripheral eosinophilia as a potential marker of underlying malignancy.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5586309"},"PeriodicalIF":0.6,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}